...
机译:基于MRNA水平的PD-L1对IVIMIMAB阶段IV阶段Melanoma的预测值
Univ Hosp Erlangen Dept Dermatol D-91052 Erlangen Germany;
Univ Hosp Erlangen Dept Dermatol D-91052 Erlangen Germany;
Univ Hosp Zurich Dept Dermatol Zurich Switzerland;
Univ Hosp Tubingen Dept Dermatol Tubingen Germany;
Univ Hosp Erlangen Div Mol &
Expt Surg Erlangen Germany;
Univ Hosp Erlangen Dept Dermatol D-91052 Erlangen Germany;
Univ Hosp Essen Dept Dermatol Essen Germany;
Univ Hosp Erlangen Dept Surg Erlangen Germany;
Univ Hosp Zurich Dept Dermatol Zurich Switzerland;
Univ Hosp Kiel Dept Dermatol Kiel Germany;
Univ Hosp Regensburg Dept Dermatol Regensburg Germany;
Univ Hosp Erlangen Dept Dermatol D-91052 Erlangen Germany;
Univ Hosp Erlangen Dept Dermatol D-91052 Erlangen Germany;
Univ Hosp Zurich Dept Dermatol Zurich Switzerland;
Univ Hosp Erlangen Dept Dermatol D-91052 Erlangen Germany;
Univ Hosp Erlangen Div Mol &
Expt Surg Erlangen Germany;
Univ Hosp Erlangen Dept Dermatol D-91052 Erlangen Germany;
PD-L1; Ipilimumab; Predictive marker; Prognostic marker; Checkpoint inhibitors; Melanoma; Biomarker;
机译:基于MRNA水平的PD-L1对IVIMIMAB阶段IV阶段Melanoma的预测值
机译:CTLA4启动子甲基化预测抗CTLA-4免疫疗法(IPILIMIMAB)治疗的IV阶段Melanoma中的反应和无进展存活
机译:Morphomics预测IV期黑色素瘤患者对Ipilimumab的反应
机译:退出人参皂苷Rb1慢性治疗改变了培养的大鼠海马神经元的GABAA受体mRNA水平
机译:纳秒电脉冲后,鼠B16-F10黑色素瘤细胞的附着能力和黑色素瘤抑制活性mRNA表达水平变化。
机译:伊匹木单抗与卡铂/紫杉醇的II期临床试验在不可切除的III期或IV期黑色素瘤中发现的外周和局部预测性免疫特征
机译:CTLA4启动子甲基化预测抗CTLA-4免疫疗法(IPILIMIMAB)治疗阶段IV静脉瘤的反应和无进展存活